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Background
Vascular endothelial growth factor A (VEGF-A) is a mem-
ber of the larger family of VEGF-related cytokines that
mediates multiple functions of endothelial cells including
proliferation, migration, and permeability. Current think-
ing on the pathogenesis of communicating hydrocepha-
lus focuses on pulsatile vascular mechanisms, but the
biochemical and biological underpinnings remain
obscure. Insertion of a shunt, the most common treat-
ment of this disorder, often fails. We wished to begin
exploration of a link between hyperpulsatility and
increased VEGF, which is a potent vascular permeability
factor. The success of anti-VEGF treatments in very low
dose for edema associated with macular degeneration and
diabetic retinopathy suggest that anti-VEGF treatment in
hydrocephalus could in some cases be a therapeutic alter-
native to shunt insertion.
Materials and methods
Forty-three cerebrospinal fluid (CSF) samples of pediatric
patients undergoing intradural surgery including hydro-
cephalus were assayed by enzyme-linked immunosorbant
assay (ELISA) to measure VEGF-A level (the lowest assay
limit: 15.6 pg/ml). For pair-wise comparison, the Mann-
Whitney test was used between the control (n = 23) and
hydrocephalic group (n = 20).
Results
ELISA demonstrated that the CSF VEGF-A in hydro-
cephalic patients was elevated over controls (median, 63
and 15.6 pg/ml, respectively). Specifically, Mann-Whitney
and Wilcoxon tests indicated that the two patient groups
of control and hydrocephalus differ in CSF VEGF-A (pg/
ml) at 95% confidence level (p = 0.00033). Indeed,
patients with other conditions of altered CSF flow path-
ways, which would also be expected to interfere with the
intracranial or intraspinal pulsation absorption mecha-
nisms (as in Chiari malformations, some arachnoid cysts,
and the like) also had elevations in CSF VEGF-A.
Conclusion
Forty-three pediatric cases demonstrated that CSF VEGF-A
was significantly higher in the group with hydrocephalus.
This suggests that VEGF-A may play an important role in
the pathogenesis of hydrocephalus and inhibition of
VEGF-A may be a potential therapeutic approach.
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